A few years back, I wrote an article titled, “700 Million Reasons to Question Everything Venture Capitalists Do.” Why 700 million? Because that was DoorDash’s “disappointing” valuation at the time. It was seen as an indication that VCs might finally be coming to their senses after a year of seemingly round-the-clock unicorn production — 10 a month — that ended with a $9 billion bang: the Theranos blood-testing debacle. READ MORE